Placebo to remibrutinib (LOU064) 25 mg film-coated tablet, -, LOU064, -
CLOU064A2303B
Phase 3 small_molecule active
Quick answer
Placebo to remibrutinib (LOU064) 25 mg film-coated tablet, -, LOU064, - for Chronic Spontaneous Urticaria is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Chronic Spontaneous Urticaria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active